Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
March 06, 2025 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
February 11, 2025 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
February 05, 2025 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
January 06, 2025 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage...
Algernon Announces Warrant Extension
November 04, 2024 18:30 ET
|
Algernon Pharmaceuticals Inc.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals...
Algernon Pharmaceuticals Announces Closing of Private Placement
August 20, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Pharmaceuticals Announces Increase to Private Placement
August 13, 2024 07:18 ET
|
Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Pharmaceuticals Announces Private Placement
August 07, 2024 17:02 ET
|
Algernon Pharmaceuticals Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN)...
Algernon Pharmaceuticals Announces Closing of Private Placement
August 02, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...
Algernon Pharmaceuticals Announces Increase to Private Placement
July 31, 2024 07:00 ET
|
Algernon Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage...